Jagsonpal Pharmaceuticals Limited has announced the availability of the audio recording from its Q3 FY26 earnings conference call, providing stakeholders with access to detailed discussions about the company's quarterly financial performance. The pharmaceutical company has made this recording available in compliance with regulatory requirements and to ensure transparency with investors and market participants.

Earnings Call Details

The company held its Q3 FY26 earnings conference call on January 22, 2026, at 5:00 PM to discuss the financial results for the third quarter of fiscal year 2026. The call served as a platform for management to present the quarterly performance and address queries from analysts and investors.

Regulatory Compliance and Accessibility

The audio recording has been made available pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to disclose material information that could impact investor decisions in a timely and transparent manner.

Stakeholders can access the audio recording through the company's official website at the investor relations section under earning calls. The company had previously intimated about the earnings call through an earlier communication dated January 15, 2026.

Corporate Information

Jagsonpal Pharmaceuticals Limited operates from its corporate office located in Gurugram, Haryana. The company is listed on both major Indian stock exchanges with specific trading identifiers for investor reference.

The announcement was signed by Pratham Rawal, Company Secretary and Compliance Officer, ensuring proper authorization and compliance with corporate governance standards. This disclosure demonstrates the company's commitment to maintaining transparent communication with its stakeholders and adhering to regulatory requirements for listed entities in the Indian capital markets.

Jagsonpal Pharmaceuticals Limited has announced a conference call with analysts and investors to discuss its Q3FY26 financial results. The pharmaceutical company informed stock exchanges about this investor engagement activity through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The earnings conference call is scheduled for Thursday, January 22, 2026, at 5:00 PM IST. Go India Advisors will host the session, which aims to provide insights into the company's third-quarter performance for fiscal year 2026.

Key Participants

The conference call will feature senior management representatives from Jagsonpal Pharmaceuticals, ensuring comprehensive coverage of the company's quarterly performance and strategic initiatives.

Access Information

The company has provided multiple options for participants to join the conference call. Attendees can pre-register to avoid wait times and join with a "Diamond Pass" for priority access. Universal dial-in numbers have been made available for those preferring traditional phone access.

Dial-in Details:

• Universal Numbers: +91 22 6280 1557 / +91 22 7115 8383
• Recommendation: Dial-in 5-10 minutes prior to scheduled time
• Registration: Pre-registration link provided for seamless access

Contact Information

For additional information regarding the conference call, participants can reach out to Go India Advisors representatives Soumya Chhajed ( soumya@goindiaadvisors.com ) and Sheetal Khanduja ( sheetal@goindiaadvisors.com ). The regulatory filing was signed by Company Secretary & Compliance Officer Pratham Rawal on January 15, 2026.